4 / 2338

Flagship’s Afeyan Sees UK Bet Creating Next Moderna

TL;DR

Flagship Pioneering founder and CEO Noubar Afeyan says the biotech venture firm hopes its new UK investment can grow to as much as £600 million “relatively soon,” as it establishes its first full-scale company-creation operation outside the US. Speaking on Bloomberg’s “The Pulse With Francine Lacqua”, the Moderna co-founder explains why Flagship chose the UK, how AI could accelerate drug discovery and the creation of new biotech companies, and why governments and industry need agreed safeguards for increasingly autonomous AI agents.

Nauti's Take

For small teams, the practical test is the handoff between an AI agent and a laboratory or business process: which decisions can it make autonomously, what data does it use, and where is an auditable approval required? Before scaling the setup, teams should measure real time savings and the cost of human oversight in one tightly bounded drug discovery or research workflow.

Sources